PATENT CLAIM ANALYSIS

Application Number: 15868469
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "172100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Claim (Index 17):
A method of treating cancer comprising administering at least one immune checkpoint inhibitor, wherein the immune checkpoint inhibitor comprises an antibody specific for at least one of CTLA-4, PD-1, TIM-3, LAG-3, PD-L1, B7-H3, B7-H4, BTLA, ICOS, or OX40, and at least one rexinoid active agent wherein the at least one rexinoid active agent comprises Retinoic X Receptor (RXR) antagonist means.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.16
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15620411', '15868450', '15868459', '14507730', '15341969']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8161493233423075
- 35 USC 102 Novelty (BERT): 0.652770435490107
- Combined Prediction Score: 0.7998114345570875
- Mean Citation Score: 481.98090600000006
- Max Citation Score: 611.9661
- Similarity Product: 550.459137414372

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test